The BPC-157/TB-500 blend sits entirely outside the framework that governs medicines in the United States. Neither peptide has FDA approval for any human use, the combination has never been evaluated as a drug, and the two are sold almost exclusively under research use only or not for human consumption labeling that keeps them in the chemical-supply channel rather than the medical one. The practical reality for anyone weighing the blend is that no regulator recognizes it as an approved product, and its legal exposure lands hardest on the people who sell it.
The BPC-157/TB-500 blend has no regulatory approval, no compounding eligibility, and no pathway of its own in the United States, and both peptides are banned at all times under the WADA Prohibited List.
Neither peptide holds FDA approval for any human indication, and no configuration of them, whether the single peptide, any dosage form, or the combined blend, is a recognized medicine. The distinction that matters is between an approved drug that has cleared adequate and well-controlled trials for a specific labeled use and an investigational or unstudied substance that has not. TB-500's parent molecule reached early clinical study, but that investigational history is not approval.
| Approval dimension | BPC-157 | TB-500 |
|---|---|---|
| FDA approval | None, no New Drug Application | None, not a licensed drug product |
| Clinical history | Never entered the approval process | Parent thymosin beta-4 studied as RGN-259 |
| Market form | Research use only compound | Research use only compound |
Neither BPC-157 nor TB-500 holds an FDA-approved indication, a New Drug Application, or accepted therapeutic labeling in any dosage form, and the combined blend inherits that unapproved status.
Research use only and not for human consumption are supply-chain designations, not a grant of legal permission to put a substance in a person. Their legitimate role is to move reagents and reference chemicals to laboratories without those chemicals being regulated as drugs. Regulators look past the words on the vial to the intended use conveyed by the whole context of the sale.
The research use only label does not convert an unapproved new drug into a legal one, and regulators judge intended use by the totality of the sale rather than by the disclaimer on the vial.
The FDA sorts bulk drug substances that pharmacies nominate for compounding under section 503A into categories that signal whether the agency is comfortable with their use pending formal rulemaking. Category 2 is reserved for substances that raise significant safety concerns, where the agency will not extend the same enforcement discretion. That categorization reflects the current state of evidence rather than a permanent verdict, and BPC-157's standing has since moved.
The FDA removed BPC-157 and TB-500 from Category 2 in April 2026 and referred them to its Pharmacy Compounding Advisory Committee, which reviewed them on July 23-24, 2026, but BPC-157 does not appear on the 503A Bulks List and remains ineligible for legal compounding.
For athletes governed by anti-doping rules both peptides are off limits, though they land on the list by different routes. TB-500 is treated as a prohibited peptide named for its tissue-repair activity, while BPC-157 is caught by a catch-all clause covering substances with no health-authority approval. Both apply at all times, in and out of competition.
| Anti-doping dimension | TB-500 | BPC-157 |
|---|---|---|
| Basis of the ban | Prohibited peptide, thymosin beta-4 fragment | Catch-all: no approval by any health authority |
| When prohibited | At all times, in and out of competition | At all times, in and out of competition |
| Consequence of a positive test | Anti-doping rule violation, multi-year ineligibility | Anti-doping rule violation, multi-year ineligibility |
TB-500 is banned by name as a prohibited peptide and BPC-157 is captured by WADA's catch-all clause for substances with no health-authority approval, so both are prohibited at all times, in and out of competition.
Distributors carry the heaviest legal exposure in this market. Selling either peptide for human use means introducing an unapproved new drug into interstate commerce, a prohibited act under the Federal Food, Drug, and Cosmetic Act, and the typical presentation adds misbranding through inadequate directions and unsubstantiated claims. That exposure climbs sharply the moment the marketing shifts from selling a chemical to promoting a human benefit.
Selling BPC-157 or TB-500 for human use introduces an unapproved new drug into interstate commerce under the FDCA, exposing distributors to warning letters, seizure, injunctions, criminal referral, and FTC deceptive-advertising and product-liability claims.
The buyer's exposure looks different from the seller's, driven more by product uncertainty and anti-doping rules than by criminal drug law. Neither peptide is a federally scheduled controlled substance, so simple personal possession is generally not a drug crime, and the weight of the FDCA falls on the party introducing the drug into commerce. The real pressure points sit elsewhere, and they depend on who the buyer is.
An individual buyer faces little criminal drug-law exposure because neither peptide is federally scheduled, but a competitive athlete using either commits a sanctionable anti-doping violation, imported shipments can be seized at the border, and a buyer harmed by an unregulated vial has weak legal recourse.
Legal treatment varies because every country runs its own medicines-approval and import regime, and an unapproved peptide slots differently into each one. What stays constant is that neither peptide is an approved medicine anywhere, so nowhere is the blend a normal, freely prescribable drug. Import and customs rules often matter more in practice than the abstract legal status.
Neither peptide is an approved medicine in any country, strict regimes such as EMA member states, the UK, Australia, and Canada bar its supply as a medicine, and import or customs seizure often matters more in practice than whether possession is prosecuted.
The blend has no regulatory pathway of its own, and combining the two peptides creates no new legal standing. Under the drug-approval framework a fixed combination is itself a distinct drug product that would have to be approved on its own evidence, showing the specific combination is safe and effective and that each component contributes to the claimed effect. The mixture has never been through any such evaluation.
The BPC-157/TB-500 blend has no regulatory pathway of its own, and because a fixed combination must be approved on its own evidence, the untested mixture inherits the unapproved status of both peptides rather than gaining any standing by being combined.
Educational use only. This article describes what the published scientific and clinical literature reports about BPC-157/TB-500 Blend. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
